Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. - Wikidata - awgldk - TriplyDB

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q33594805

about

Functional correction of dystrophin actin binding domain mutations by genome editing.Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets.Skipping Multiple Exons to Treat DMD-Promises and Challenges.Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.Effect of Muscle Strength by Trichinella spiralis Infection during Chronic Phase.

P2860

Q42162721-4B88E7EB-BA8F-4FF0-8958-E4FFF65FC202 Q47700306-2840A20D-1E78-4F74-84A9-CD3969362550 Q51246185-3EB22F4D-6C7E-4209-8F3A-128AAB2F6FD7 Q52429827-90BC15A8-E29D-4D3E-9BFF-DB487CD9500A Q55277079-CF09FAA5-33C4-4210-800A-28F42905C11E Q55383414-9E2F49FD-2437-44CA-9682-6628CF1095F3 Q55638503-802A1ECC-6A8E-4E5C-94F1-4CB9E42B5A15 Q55647730-416729D0-7BA1-4892-88D2-00144E44F030

P2860

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q33594805

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@ast

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@en

type

label

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@ast

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@en

prefLabel

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@ast

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@en

P1433

Q33594805-9E94344A-302D-4E56-998E-8C42D9E7CDFA

P1476

Q33594805-E8394EEC-2B52-4F14-9AEE-08A006506B5E

P2093

Q33594805-07EEF56B-BE9E-4F3A-9B07-8B027C3FDE2A

Q33594805-17847298-8BD8-4196-9995-A2E7FB1CECBC

Q33594805-22F94A02-5FD9-4574-9335-39C9727B03B6

Q33594805-2A5D9EFD-7BEE-4967-9B53-A42A7542E1E3

Q33594805-46073DC2-1715-40B0-8EF4-C0377713DE7B

Q33594805-5228AA2E-3048-4AA5-8EB3-95091CF08CBA

Q33594805-5F40BCA1-FDC5-41BA-841A-EC984CD7D450

Q33594805-8620FC0E-4A8E-4784-825F-F3071AD3B631

Q33594805-A607ADD2-7524-4FB0-A736-D8E795A6A3E4

Q33594805-ABA39855-EC7E-4EE1-95A5-4CD05A0571A8

P2860

Q33594805-05CAF8B3-B8B0-47B3-A2ED-9013450B9C94

Q33594805-07410FA3-76AC-47F6-884C-7F61B7708E17

Q33594805-13B960E8-0D47-470B-BBF2-3E82BF00DEFA

Q33594805-144EFCAF-C7D3-4BD0-B268-B4CC57975412

Q33594805-15BAF82C-0083-4703-A08C-94487455B767

Q33594805-172BF21A-5937-4828-90BA-E2C82292BDE1

Q33594805-1A3CBA1D-8E1F-4680-B300-CCCF95B50AD0

Q33594805-27E7A526-3844-4B6D-9F0D-FF35323C24C7

Q33594805-2957E038-2C9A-46F1-B350-5DD0BD5D02A4

Q33594805-2D1566C8-7A0A-4324-9198-6AC94BBBF398

P304

Q33594805-9B7F4098-2FAA-4827-87C8-FA9BA24D31EC

P31

Q33594805-86A42E8C-4814-4355-87EE-BCA8FCA962FC

P356

Q33594805-623E2708-71E4-4913-994A-4515D339FE94

P407

Q33594805-54CC26F1-64CD-41FC-8287-6E1A267766D2

P433

Q33594805-3042506A-F91F-433E-9F21-B6AC6A727539

P478

Q33594805-BC7999BB-6030-4392-9D36-6785B43E5232

P50

Q33594805-27779582-7CD9-45B6-BF37-8A1A8D3A9032

Q33594805-5860CE87-40FE-4CFA-975E-99157CFECA67

Q33594805-C2BC08EA-BC65-4445-9A35-5430269AF7FD

P577

Q33594805-2116BDBF-EE65-4DA9-B853-C3139F84F3D9

P698

Q33594805-5B883314-DB85-4BCC-AF5D-68C7395FBC25

P932

Q33594805-067EC956-B119-4F58-9330-BB00A0CA6A65

P356

PNAS.1613203114

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Effects of systemic multiexon ...... f Duchenne muscular dystrophy.

@en

P2093

Akinori Nakamura

http://www.w3.org/2001/XMLSchema#string

Dharminder Panesar

http://www.w3.org/2001/XMLSchema#string

Hong M Moulton

http://www.w3.org/2001/XMLSchema#string

Kenji Rowel Q Lim

http://www.w3.org/2001/XMLSchema#string

Mutsuki Kuraoka

http://www.w3.org/2001/XMLSchema#string

Nhu Trieu

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Urasawa

http://www.w3.org/2001/XMLSchema#string

Peter Sazani

http://www.w3.org/2001/XMLSchema#string

Rika Maruyama

http://www.w3.org/2001/XMLSchema#string

Shin'ichi Takeda

http://www.w3.org/2001/XMLSchema#string

P2860

Dystrophin-deficient large animal models: translational research and exon skipping

Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies.

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.

Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.

One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.

P304

4213-4218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1613203114

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Yusuke Echigoya

Patrick L Iversen

P577

2017-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28373570

http://www.w3.org/2001/XMLSchema#string

P932

5402437

http://www.w3.org/2001/XMLSchema#string